Drug Profile
Levamlodipine - Sepracor
Alternative Names: S-amlodipineLatest Information Update: 21 Nov 2021
Price :
$50
*
At a glance
- Originator Sepracor
- Class Antihypertensives; Dihydropyridines; Nicotinic acids; Small molecules
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Angina pectoris; Hypertension
Most Recent Events
- 02 Nov 2005 Levamlodipine is available for licensing in USA (http://www.sepracor.com)
- 06 May 2002 Phase-II clinical trials in Hypertension in USA (unspecified route)
- 29 Oct 1998 New profile